Equity research analysts covering KORU Medical Systems (traded under the ticker KRMD) generally maintain a favorable consensus outlook, with multiple tracking institutions rating the small-cap medical technology enterprise as a buy. Optimistic evaluations are driven by expanding adoption rates of its proprietary subcutaneous infusion systems and commercial growth pipelines. However, because small-cap healthcare equities experience considerable market volatility and operating losses, individual investors must weigh their risk appetite against clinical milestones before deciding to buy, sell, or hold.